Phase 3 N=38 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Survival and Success of MIS C1 Implants- a Field Study
Failure of Osseointegration of Dental Implant
Primary: Survival Rate — 115 dental implants
Phase 2 N=60 The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis
Peri-implantitis
Primary: Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket — -2.13; -1.79 mm — p=0.1629
N/A N=82 Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
Phase 3 N=533 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Melanoma
Primary: Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events — 7; 7; 0; 0 Participants
Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Phase 3 N=744 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
Episodic Migraine
Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) — 78.6; 67.0 percentage of participants
Phase 3 N=906 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Melanoma
Primary: Recurrence-free Survival (RFS) — 52.37; 24.08 Months — p=0.0003
N/A N=368 User Performance Evaluation for DARIO™ BGMS
Diabetes
Primary: Accuracy - Blood Glucose Level Obtained by Layperson With the Dario Meter Compared to Blood Glucose Level on Yellow Springs Instrument Obtained by Nurse/Technician — 12…
Phase 3 N=359 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Colitis, Ulcerative
Primary: Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic…
Phase 2 N=51 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
Muscular Atrophy, Spinal
Primary: Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of >/=20kg — 5 milligram (mg)
Phase 2 N=1,066 Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
Heart Failure
Primary: Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90 — 37.2; 30.9; 32.5; 37.3 Percentage of participants — p=0.8771
Phase 2 N=165 Combining Varenicline and Naltrexone for Smoking Cessation
Nicotine Dependence · Alcohol Use Disorder
Primary: Number of Participants With Expired Carbon Monoxide Level <=5ppm — 22; 37 Participants
Phase 2 N=32 Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Non-healing Wound · Non-healing Diabetic Foot Ulcer · Diabetic Foot Infection
Primary: Number of Subjects With Complete Wound Healing — 16 participants
Phase 4 N=138 Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
Breast Cancer
Primary: Comparison of Cumulative Incidence of Anti-pegfilgrastim Antibodies (Binding and Neutralizing) to Pegfilgrastim Between Treatment Groups at the End of Cycle 4 (Day 84)…